New Hep C drug gets PBS listing

Another direct-acting antiviral (DAA) will be listed on the PBS on 1 January.

Elbasvir and grazoprevir (marketed as Zepatier) has been indicated for the treatment of chronic hepatitis C virus genotype 1 and 4 infection in adults. It was TGA-approved in August this year.

The drug is a once-daily tablet taken for 12 weeks and has a 95-98% cure rate.